Pharmacy news

• AXS26 Panel: Keep Cybersecurity Top of Mind

  20-10-2026 05:58 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksRansomware attacks that prevent e-prescribing and firewall breaches that provide a direct line to protected health information are among cybersecurity risks pharmacists face daily, whether operating independently, within a chain, or in a health system. Speakers at Asembia’s AXS26 Summit, in Las Vegas, stressed the importance of cybersecurity strategy.“As a pharmacist myself, I know how comple
  
  Read more

• Expert Strategies for Surviving IVWMS Downtimes

  22-10-2026 02:00 via Pharmacy Practice News
  
  By Gina ShawWhen an IV workflow management system (IVWMS) goes down, staff accustomed to relying on it must switch to manual procedures, often under pressure. Those skills can fade without practice, two sterile compounding experts told attendees at NHIA26, in Denver.“Training staff in manual processes is essential, and you need redundancy in place wherever possible, especially for equipment such as ACDs [automated compounding devices] and compounding pumps,” said Glen Gard, CPhT-Adv, CSPT, a
  
  Read more

• First mRNA Flu Vaccine Puts Pharmacists on Counseling Front Line

  21-10-2026 17:00 via Pharmacy Practice News
  
  By Fran KritzThe FDA’s approval of the first mRNA influenza vaccine, Moderna’s mRNA-1010 (mFlusiva), is likely to prompt questions from patients and clinicians, and pharmacists should be prepared to answer them.Moderna said it plans to deliver supplies “to select retailers” in time for the 2026-2027 flu season, which typically begins in October.“When there’s a new vaccine, people are often unsure about whether it works and what their experience will be,” said Brigid Groves, PharmD,
  
  Read more

• AI Helpful in Patient Care, but Always Check Its Outputs

  21-10-2026 02:00 via Pharmacy Practice News
  
  By Karen BlumArtificial intelligence can help with several administrative and clinical tasks in patient care, but clinicians are still needed to review, vet, and build on the responses generated by AI tools, speakers said during the ASPEN 2026 Nutrition Science & Practice Conference, in Long Beach, California.Summaries, Drafting, and DocumentationOn the administrative side, AI tools can be used to review and summarize emails and help draft responses, or to sort emails into categories and fla
  
  Read more

• Advertisement

• FDA Compounding Panel Backs 6 of 7 Peptides Despite Safety Risks in Oversight and Production

  20-10-2026 15:00 via Pharmacy Practice News
  
  By Gina Shaw Rita Jew, PharmDThe FDA Pharmacy Compounding Advisory Committee’s (PCAC’s) recommendation that six of seven peptides be added to the 503A bulk drug substances list has alarmed leading medication safety experts.The move departs from the evidence-based process the agency normally follows and leaves several unresolved safety questions in place, noted Rita Jew, PharmD, the president of the Institute for Safe Medication Practices (ISMP), part of ECRI. Demand for peptide produ
  
  Read more

• FDA Approves Zilucoplan Once-Daily Autoinjector for Generalized Myasthenia Gravis

  20-10-2026 13:39 via Pharmacy Practice News
  
  By PPN StaffThe FDA has approved zilucoplan (Zilbrysq, UCB) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody–positive.Zilucoplan is the first self-administered, once-daily autoinjector administration option for this form of gMG. The autoinjector is designed to automatically deliver a predetermined dose when activated against the skin to ease the self-administration process.“For a chronic condition like gMG, having differe
  
  Read more

• Does a Designated Pharmacist Improve OPAT Outcomes?

  20-10-2026 11:10 via Pharmacy Practice News
  
  By Meaghan Lee Callaghan and Landon GrayDoes including a designated pharmacist in managing outpatient parenteral antimicrobial therapy (OPAT) improve patient outcomes?A new study presented at MAD-ID x SIDP 2026 suggests yes, but more research is needed.Study authors Meg Parmalee, PharmD, a PGY-2 oncology pharmacy resident, and Tamanna Talwar, PharmD, a PGY-1 ambulatory pharmacy resident, both at UNC Health, in Chapel Hill, North Carolina, spoke with Infectious Disease Special Edition at the conf
  
  Read more

• Smart Pump–EHR Interoperability: Big Promise, Thin Evidence to Date

  19-10-2026 14:30 via Pharmacy Practice News
  
  By Marcus A. BanksConnecting smart infusion pumps directly to the electronic health record (EHR) has the potential to reduce medication errors, streamline nursing workflow, and improve charge capture, but the evidence supporting these gains is still immature, according to a recent systematic review (Intensive Crit Care Nurs 2026;97:104475).Interoperability allows a verified EHR order to auto-program the infusion pump and pump to auto-document the infusion back into the record, reducing manual ke
  
  Read more

• Advertisement

• Building a CAR-T Bridge With Bispecifics for Lymphoma

  18-10-2026 02:00 via Pharmacy Practice News
  By Gina ShawBispecific antibodies (BiAbs) are achieving impressive results, in some cases more than doubling the survival gains seen with conventional chemotherapy. These advances are pushing oncology teams to reconsider whether these powerful anticancer drugs can be used earlier to carry more patients to potentially curative cellular therapy, speakers noted during a session at HOPA26, in New Orleans.Glofitamab-gxbm (Columvi, Genentech) is a case in point. When added to gemcitabine and oxaliplat
  
  Read more

• Ascension Error Exposes Gaps Hospitals Should Audit Now

  17-10-2026 14:00 via Pharmacy Practice News
  
  By Gina ShawPharmacy leaders should use the medication error that severely injured four joint replacement patients at Ascension Saint Thomas Hospital Midtown, in Nashville, Tennessee, as a prompt to examine their own sterile compounding safeguards—particularly barcode overrides, batch preparation, high-alert medication storage, technician competency assessment, and final pharmacist verification, medication safety experts said.The Tennessee Health Facilities Commission’s 80-page surve
  
  Read more

• SCCM Speakers: AI Tools Require Strong Governance and Rigorous Vetting

  17-10-2026 02:03 via Pharmacy Practice News
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Marcus A. BanksArtificial intelligence tools for clinical decision-making hold promise but may not be ready for everyday use, according to a discussion forum at the 2026 Critical Care Congress, in Chicago. Financial limitations may impede AI adoption as well.“The AI tools that are the most validated, as with sepsis detection, require institutional purchase before people can access them. Given financial constraint
  
  Read more

• SenderraRx Earns ACHC Reaccreditation in Specialty Pharmacy and Oncology Distinction

  16-10-2026 12:29 via Pharmacy Practice News
  Originally published by our sister publication Specialty Pharmacy ContinuumSenderra Specialty Pharmacy announced that it has earned reaccreditation in Specialty Pharmacy from the Accreditation Commission for Health Care (ACHC), including a Distinction in Oncology. Reaccreditation reflects an independent evaluation against nationally recognized standards for specialty pharmacy quality, safety, and patient care. The Oncology Distinction recognizes Senderra’s oncology-focused clinical oversig
  
  Read more

• Digital Supply Chain Pilot Targets Oncology Drug Shortages

  16-10-2026 03:55 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina Shaw April GilesA first-of-its-kind supply chain transparency initiative has demonstrated that hospitals, distributors, and other stakeholders can share sensitive inventory data across organizational boundaries—and that doing so creates real planning value even when no drug shortage is underway.The Drug Resiliency & Transparency Pilot, led by the End Drug Shortages Alliance (EDSA), emerged from an August
  
  Read more

• Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer

  15-10-2026 20:59 via Pharmacy Practice News
  
  Originally published by our sister publication Clinical Oncology NewsCHICAGO—Adding perioperative apalutamide (Erleada, Johnson & Johnson) to androgen deprivation therapy (ADT) delays the risk for metastasis or death and significantly improves pathologic response rates in patients with high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy, according to the phase 3 PROTEUS trial.Investigators said the results, which were presented at the 2026 American
  
  Read more

• FDA Finalizes Guidance to Broaden Cancer Trial Eligibility

  15-10-2026 02:00 via Pharmacy Practice News
  
  By Jennifer KulpaThe FDA has finalized three guidance documents urging sponsors to ease overly restrictive eligibility criteria in cancer clinical trials. The recommendations address performance status, washout periods and concomitant medications, and laboratory values, potentially expanding enrollment to more patients treated in ambulatory settings.Issued in July 2026 by the FDA’s Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation a
  
  Read more

• FDA Approves Hovilpri for Refractory HSV Lesions

  14-10-2026 13:26 via Pharmacy Practice News
  
  Originally published by our sister publication Infectious Disease Special EditionBy Meaghan Lee CallaghanThe FDA has approved pritelivir (Hovilpri, Asahi Kasei) for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, famciclovir, or valacyclovir in immunocompromised adults.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller;
  
  Read more

• The Backup for Drug Shortages Is Required by Law to Arrive Late

  14-10-2026 13:15 via Pharmacy Practice News
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Dalbir BainsAmerica's backup supply of sterile drugs is required by law to arrive late.Start with the scoreboard. ASHP counted
  
  Read more

• Medicaid Makes the Case for Food as Medicine

  14-10-2026 04:41 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawMedically tailored meals delivered to high-risk Medicaid members were associated with 31% fewer hospitalizations, 20% fewer emergency department visits, and $3,433 lower total healthcare costs per person, in the largest real-world evaluation of the intervention to date.The cost reductions offset 98% of program costs, and among participants with cardiovascular disease, kidney disease, diabetes, depression, or h
  
  Read more

• Pestle and CriticalPoint Announce Partnership to Connect Compounding Education with Pharmacy Compliance Management

  13-10-2026 18:37 via Pharmacy Practice News
  Pestle, a pharmacy compliance and compounding workflow software, today announced a partnership with CriticalPoint by TRC Healthcare to connect compounding education with the training and compliance activities pharmacies manage in Pestle. Through the partnership, Pestle clients can purchase CriticalPoint education programs and access relevant courses directly from their Pestle training assignments.The partnership brings together CriticalPoint’s compounding education and Pestle’s tools
  
  Read more

• Solid Tumor Therapeutics: What’s New?

  13-10-2026 03:34 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy ContinuumHeather Ipema, PharmD, BCPSClinical Associate Professor, Drug Information SpecialistUniversity of Illinois Chicago Retzky College of PharmacySolid tumors are among the most common tumor types, comprising 8 of the top 10 most common cancers in men and women.1 Estimates for 2026 list lung cancer, colorectal cancer, and skin melanoma as the most likely new cancer diagnoses in men, and breast, lung, and colorectal as the most
  
  Read more

• Copay Programs, Coupons And Other Risky MC Maneuvers

  12-10-2026 03:28 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawAs pharmacy benefit managers (PBMs) expand the use of copay accumulators, copay maximizers, alternative funding programs (AFPs), and prescription discount cards, specialty pharmacies are finding themselves caught in benefit designs that shift financial risk while obscuring who ultimately controls access to therapy.These programs are drawing heightened scrutiny as specialty drug spending continues to rise, manu
  
  Read more

• Combination bnAbs Sustained Viral Suppression in Children After ART Interruption

  11-10-2026 05:20 via Pharmacy Practice News
  
  Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyCombination broadly neutralizing antibodies (bnAbs) maintained viral suppression for 24 weeks in the first children in Botswana with HIV to receive dual- or triple-bnAb treatment after scheduled antiretroviral (ART) therapy interruption, according to preliminary findings (abstract 152) presented at CROI 2026, in Denver.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em
  
  Read more

• Brief Caregiver Education Boosts TD Evaluation and Diagnosis

  10-10-2026 02:18 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawA single 10- to 15-minute online education
  
  Read more

• FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia

  09-10-2026 14:24 via Pharmacy Practice News
  
  By PPN StaffThe FDA approved olanzapine as an extended-release injectable suspension (Weltruza, Teva) for the treatment of schizophrenia in adults.With the approval, the drug becomes the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of schizophrenia in adults. It does not require loading doses, oral supplementation, or post-injection monitoring.Extended-release injectable olanzapine “combines proven science and novel formulation
  
  Read more

• FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism

  09-10-2026 13:53 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By PPN StaffThe FDA approved remibrutinib (Rhapsido, N
  
  Read more

• Registry Data Support Treating Mild Tardive Dyskinesia

  09-10-2026 02:16 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPatients whose tardive dyskinesia (TD) rate
  
  Read more

• Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment

  08-10-2026 12:00 via Pharmacy Practice News
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawPharmacists are well positioned to lead revenue cycle management for infused medications because they can follow a dru
  
  Read more

• In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s

  08-10-2026 12:00 via Pharmacy Practice News
  
  figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon Group.By Gina ShawAfter Beth Israel Lahey Health (BILH) brought its employee prescription benefit in-house and began requiring employee
  
  Read more

• Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests

  08-10-2026 03:14 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }©McMahon GroupBy Gina ShawNearly one-fourth of patients with tardive
  
  Read more

• FDA Approves Degevma, Biosimilar to Xgeva

  07-10-2026 15:02 via Pharmacy Practice News
  
  Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved the biosimilar Degevma (denosumab-adet, Teva) for all indications of its reference product, Xgeva (denosumab, Amgen). These include:• preventing bone complications in adults with advanced cancer that has spread to the bone;• treating adults and skeletally mature adolescents with giant cell tumor of bone; and• treating hypercalcemia of malignancy.Degevma is Teva’s second bi
  
  Read more

Follow @newsl_pharmacy on Twitter!